Please use this identifier to cite or link to this item:
http://localhost:8080/xmlui/handle/123456789/9274
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | -Hsun Yi, Chih | - |
dc.contributor.author | -Jong Bair, Ming | - |
dc.contributor.author | -Hung Wang, Jen | - |
dc.contributor.author | Wun Wong, Ming- | - |
dc.contributor.author | Tsai Liu, Tso- | - |
dc.contributor.author | -Yi Lei, Wei | - |
dc.contributor.author | Liang, Shu-Wei | - |
dc.date.accessioned | 2024-12-19T02:39:52Z | - |
dc.date.available | 2024-12-19T02:39:52Z | - |
dc.date.issued | 2022-08-01 | - |
dc.identifier.issn | 1684-1182 | - |
dc.identifier.uri | http://localhost:8080/xmlui/handle/123456789/9274 | - |
dc.description.abstract | Abstract Background: Patient-reported outcome (PRO) in patients with chronic hepatitis C virus (HCV) infection (CHC) after successful direct-acting antiviral (DAA) therapy remains elusive. The study aimed to investigate the impact of DAA therapy on health-related quality of life (HRQoL). We also assess the associated factors predictive of HRQoL change after sustained virologic response (SVR) to HCV therapy. Methods: CHC patients receiving DAA therapy were prospectively recruited. They completed paired HRQoL assessments which included Short-Form-36 (SF-36), Pittsburgh Sleep QualityIndex (PSQI) score, Taiwanese Depression Questionnaire score, and State Trait Anxiety Inventory (STAI) score before treatment and at Week 12 off-treatment. Clinical data and characteristics were compared in a paired manner. Results: A total of 158 patients achieved SVR (SVR rate: 96.6%) were enrolled into the final analysis. Improvement of depression, anxiety, digestive symptoms, and SF-36 items of vitality, body pain, physical functioning, emotional functioning, social functioning, and mental health were demonstrated among SVR patients. Sleep quality, or other SF-36 items were not significantly changed after the treatment. Multivariate analysis revealed that improvement of sleep quality, depression, and anxiety were associated with better HRQoL. Conclusion: SVR to HCV therapy by DAA significantly improved PROs including HRQoL | en_US |
dc.language.iso | en | en_US |
dc.publisher | Elsevier Taiwan LLC | en_US |
dc.subject | Quality of life; | en_US |
dc.subject | HCV; | en_US |
dc.subject | DAA | en_US |
dc.title | Improvement of patient-reported outcomes in patients achieving sustained virologic response with direct-acting antivirals for hepatitis C virus infection | en_US |
dc.type | Article | en_US |
Appears in Collections: | VOL 55 NO 4 2022 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
643-650.pdf | 396.04 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.